表紙
市場調查報告書

腫瘤浸潤性淋巴球 (TIL):癌症免疫療法新的國境

Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy

出版商 BCC Research 商品編碼 882253
出版日期 內容資訊 英文 21 Pages
訂單完成後即時交付
價格
Back to Top
腫瘤浸潤性淋巴球 (TIL):癌症免疫療法新的國境 Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy
出版日期: 2019年07月03日內容資訊: 英文 21 Pages
簡介

本報告提供癌症免疫療法新的國境的腫瘤浸潤性淋巴球 (TIL)的R&D趨勢調查,腫瘤浸潤性淋巴球 (TIL)的概要,轉移性黑色素瘤、其他腫瘤的TIL治療藥的開發趨勢,主要企業、研究中心的臨床開發趨勢等彙整資料。

第1章 使用了TIL的細胞治療的出現

第2章 轉移性黑色素瘤的TIL治療藥的開發

  • TIL的發生
  • 淋巴球乾涸的重要性
  • 白細胞介素2所扮演的角色
  • 作為主流的治療選擇的TIL的可行性

第3章 其他腫瘤類型中TIL治療藥的開發

  • 子宮頸癌
  • 卵巢癌
  • 腎臟癌
  • 消化道惡性腫瘤
  • 頭頸椎癌症

第4章 TIL治療藥臨床開發

  • Lifileucel (LN-144):Iovance Biotherapeutics
  • LN-145:Iovance Biotherapeutics
  • TILT-123:TILT Biotherapeutics
  • Optera Therapeutics Corp.
  • 其他TIL研究中心
  • 未來展望

第5章 文獻

目錄
Product Code: BIO129A

Report Highlights:

This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.

This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.

Report Includes:

  • An overview of Tumor Infiltrating Lymphocytes (TILs) for the treatment of metastatic cancer
  • Discussion of the development of TIL as a treatment option for melanoma and the possibilities to expand this therapy to other types of cancer
  • Exploration of adoptive T-cell therapy (ATCT) using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma, and the curative potential of ATCT in a variety of other solid tumors
  • Comparison between two main technologies of tumor immunotherapy, chimeric antibody receptor engineered T Cell (CAR-T) and genetically modified T cell receptors (TCR)
  • Information on the role of TILs as a strong prognostic biomarker for triple-negative breast cancer (TNBC) and their potential ramifications

Table of Contents

Chapter 1: The Emergence of Cell Therapy Using TILs

  • Introduction
  • Analyst's Credentials
  • Related Reports

Chapter 2: Development of TIL Therapies in Metastic Melanoma

  • TIL Generation Explained
  • Importance of Lymphodepletion
  • Role of Interleukin-2
  • Feasibility of TIL as a Mainstream Treatment Option

Chapter 3: Development of TIL Therapies in Other Tumour Types

  • Cervical Cancer
  • Ovarian Cancer
  • Kidney Cancer
  • Gastrointestinal Cancer
  • Head and Neck Cancers

Chapter 4: Clinical Development of TIL Therapies

  • Lifileucel (LN-144), Iovance Biotherapeutics
  • LN-145, Iovance Biotherapeutics
  • TILT-123, TILT Biotherapeutics
  • Optera Therapeutics Corp.
  • Other Centers Conducting TIL Research
  • Future Perspectives for TIL

Chapter 5: References

List of Tables

  • Table 1: TILs and Tumor Specific Antigens
  • Table 2: Adoptive T-Cell Therapy (ATC) Cellular Therapies
  • Table 3: Clinical Trials Studying TIL Therapies

List of Figures

  • Figure 1: Generation of Tumor Infiltrating Lymphocytes
  • Figure 2: IL-2 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types
  • Figure 3: TILT Biotherapeutics Development Pipeline
Back to Top